Optimising next-generation oncology treatments with companion diagnostics

By Kevin Robinson | Published: 23-Jun-2025

With tissue-based companion diagnostics (CDx) emerging as critical tools to precisely match patients to advanced treatments, cancer treatment has been revolutionised by the emergence of targeted therapies

You need to be a subscriber to read this article.
Click here to find out more.

Dr Kevin Robinson (KSR) spoke to Jessica Baumann (JB), Medical Director, Companion Diagnostics and Advanced Assays, Leica Biosystems (pictured), to find out how technologies like multiplexing, spatial profiling and AI are driving this evolution.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
  2. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like